Key facts
- Notable investors include Fifty Years, MBX Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Enoda Cellworks
- ·The full record, as it builds
Funding rounds
No funding rounds for Enoda Cellworks are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enoda Cellworks
Developer of synthetic biology-based cell therapy engineering platforms designed to optimize cellular phenotypes for therapeutic applications. The company offers a platform that integrates molecular tooling, high-throughput screening, and systems immunology to precisely engineer cell types and functions tailored for specific indications, enabling biopharmaceutical developers and research institutions to create advanced cell therapies with improved efficacy and targeted disease-fighting capabilities.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2022
- Employees
- 7
- Website
- enoda.bio/
- Ownership
- Privately Held (backing)
Enoda Cellworks doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enoda Cellworks shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enoda Cellworks in its N-PORT filings yet. We sweep new filings monthly.